Fondazione Italiana Linfomi - Ets

This study is for people with early-stage follicular lymphoma, a slow-growing blood cancer. It compares standard radiation therapy alone to radiation plus a drug called obinutuzumab. The goal is to see if adding the drug helps keep the cancer from coming back longer. About 190 pa…

This study tests whether adding daratumumab to two standard drugs (bortezomib and dexamethasone) can shrink tumors in people with a rare, aggressive blood cancer called plasmablastic lymphoma that has returned or not responded to prior therapy. About 28 adults will receive the co…

This study tests whether a targeted drug called loncastuximab tesirine can help people with mantle cell lymphoma whose cancer came back or didn't respond to previous treatments, including BTK inhibitors. About 49 adults will receive the drug after a short course of chemotherapy. …

This study tests adding the immunotherapy drug atezolizumab to standard chemotherapy (BEGEV) for people with Hodgkin's lymphoma that has returned or not responded to first treatment. About 122 adults aged 18-60 who are eligible for a stem cell transplant will take part. The goal …

This study tests a combination of two drugs (rituximab and CC-99282) as a first treatment for older, frail patients newly diagnosed with diffuse large B-cell lymphoma who cannot receive standard chemotherapy. About 47 participants will receive this chemo-free regimen to see if it…

This study tests a combination of two drugs, mosunetuzumab and zanubrutinib, in people with follicular lymphoma that has come back or not responded to prior treatment. The goal is to see if the combo can shrink tumors and improve response rates. About 56 adults will receive the t…

This study tests a drug called tislelizumab as a first treatment for adults with Hodgkin lymphoma who cannot receive standard chemotherapy due to age or other health issues. The goal is to see if the drug can shrink or control the cancer. About 28 participants will take part in t…

This study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma. It involves 552 adults aged 18-50 who have been in remission for 3 to 10 years. Participants will either receive the lifestyle plan o…

This study follows 150 elderly patients (70 years or older) with low-grade non-Hodgkin lymphoma to see how their quality of life changes during treatment. Researchers will use questionnaires to measure well-being and symptoms at the start, end, and one year after therapy. The goa…

This study gathers information from the medical records of 200 people diagnosed with plasmablastic lymphoma, a rare blood cancer. Researchers will analyze patient characteristics, treatments, and outcomes to better understand the disease. No new treatments or procedures are given…

This study follows 1,500 people with B-cell non-Hodgkin lymphoma in Italy who are receiving new monoclonal antibody treatments. Researchers will track how well the tumors shrink, how long patients live without the cancer getting worse, and any side effects. The goal is to see how…

This study is analyzing stored blood and tissue samples from 654 people with advanced follicular lymphoma to learn more about genetic changes linked to the disease. The goal is to find better ways to predict how the cancer will behave and respond to treatment. Participants are no…

This study looks back at medical records of 43 people in Italy diagnosed with primary cardiac lymphoma, a rare cancer of the heart. The goal is to learn more about the disease and how it is managed, to help doctors make better decisions. No new treatments are being tested; the st…

This study is observing 130 adults with B-cell non-Hodgkin lymphoma who are scheduled to receive CAR-T cell therapy. Researchers want to see if having low muscle mass (sarcopenia) affects how well the treatment works and what side effects occur. The goal is to learn whether a sim…

This study is for people with certain types of aggressive lymphoma (DLBCL or high-grade B-cell lymphoma) who have changes in the MYC gene. Researchers want to learn how these genetic changes relate to the immune environment around the tumor and how they affect treatment success. …

This study is collecting information from 400 people with cutaneous T-cell lymphoma to see which systemic (body-wide) treatments doctors actually use and in what order. The goal is to understand real-world treatment patterns, not to test a new drug. Participants must be at least …